Trading Halt
Filed with ASX · · 3 pages · English
Summary by 6ix AI
PainChek Ltd has requested a trading halt from the Australian Securities Exchange pending an announcement regarding regulatory clearance from the U.S. Food and Drug Administration. The halt will remain in effect until the earlier of the announcement or the commencement of normal trading on a specified date. This request has been approved by the Company's Board of Directors and aims to prevent uninformed trading in its securities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/trading-halt-425
Earlier from PainChek
- Compelling Clinical and Economic Results in Scottish Pilot
- Preliminary Final Report
- Strongly Supported A$7.5m Placement to Drive Int. Growth
- Final US FDA De Novo Clearance Submission Completed
- PainChek Reports Strong Quarterly Sales Growth
Later from PainChek
- PainChek FDA Cleared to Commence Sales in US$100M US Market
- PainChek Secures First US Customer Following FDA Clearance
- Response to ASX Aware Letter
- Key hire to drive Infant App in $15Bn addressable market
- Notice of Annual General Meeting/Proxy Form
Follow PainChek into a list and get an email when it puts out news.
Follow PainChek